Home/VIASURE Real Time PCR Detection Kits/Respiratory infections/MULTIPLEX Resp./SARS-CoV-2 (N1 + N2)

VIASURE Real Time PCR Detection Kits

SARS-CoV-2 (N1 + N2)

Instructions

Description

VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit is a real-time RT-PCR test designed for the qualitative detection of RNA from the SARS-CoV-2 in respiratory samples from individuals suspected of COVID-19 by their healthcare provider.

This test is intended to be used as an aid in the identification of the presence of the SARSCoV-2 viral RNA.

RNA is extracted from respiratory specimens, amplified using RT-PCR and detected using fluorescent reporter dye probes specific for SARS-CoV-2.

Specifications

Method
Real Time PCR
Specimen Type
Respiratory
Storage up to
(From production) 2 years
Storage temperature
(Also transport) Room temperature

Information

Coronavirus are enveloped non-segmented positive-sense RNA viruses and belong to Coronaviridae family.

There are six coronavirus species known to cause human diseases. Four viruses (229E, OC43, NL63 and HKU1) cause common cold symptoms and the other two (severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)) are zoonotic and producing more severe complications. SARS-CoV and MERS-CoV have caused more than 10,000 cumulative cases in the past two decades, with mortality rates of 34% MERS-CoV and 10% SARS-CoV.

In December 2019, some people that worked at or lived around the Huanan seafood market in Wuhan, Hubei Province, China, have presented pneumonia of unknown cause. Deep sequencing analysis of the respiratory samples indicated a novel coronavirus, which was named firstly 2019 novel coronavirus (2019-nCoV) and lately SARS-CoV-2.

Human-to-human transmission of the SARS-CoV-2 has been confirmed, even in the incubation period without symptoms, and the virus could cause severe respiratory illness like those SARS-CoV produced. Although the pneumonia is the principal illness associated, a few patients have developed severe pneumonia, pulmonary edema, acute respiratory distress syndrome, or multiple organ failure and death. Centers of Disease Control and Prevention (CDC) believes that symptoms of SARS-CoV-2 may appear in as few as 2 days or as long as 14 days after exposure, being the most common fever or chills, cough, fatigue, anorexia, myalgia and dyspnea. Less common symptoms are sore throat, nasal congestion, headache, diarrhea, nausea and vomiting. Loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms has also been reported. Older adults and people who have severe underlying medical conditions like heart or lung disease or diabetes seem to be at higher risk for developing more serious complications from COVID-19 illness.

Diagnosis of SARS-CoV-2 is performed detecting conventional causes of pneumonia early and detected by nextgeneration sequencing or real-time RT-PCR methods. Several assays that detect the SARS-CoV-2 have been are currently available, such as China CDC (gene targets, ORF1ab and N), Charité – Germany (gene targets, RdRP and E) or US CDC (two targets in N gene).

CDC recommends upper respiratory tract specimens (nasopharyngeal (NP) swab, oropharyngeal (OP) swabs, nasal mid-turbinate swab, nasal swab, nasopharyngeal wash/aspirate or nasal wash/aspirate (NW) specimens collected mainly by a healthcare provider) and/or lower respiratory specimens (sputum, endotracheal aspirate, or bronchoalveolar lavage in patients with more severe respiratory disease) for the identification of SARS-CoV-2. In addition, other clinical specimens as blood, urine and stool may be collected to monitor the presence of the virus.

Utilizamos cookies propias y de terceros para mejorar su experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies. Ok